| Name | DL-Thioctic Acid |
|---|---|
| Synonyms |
(S)-6,8-Thioctic acid (S)-1,2-Dithiolane-3-pentanoic acid
DL-Thioctic acid (+-)-2-dithiolane-3-pentanoicacid 5 MG PNPP SUBSTRATE TABLETS LIPOIC ACID, DL-ALPHA 5-(1,2-Dithiolan-3-yl)pentanoic acid R(+)-Alpha-LipoicAcid Alpha sulfur acid MFCD00005474 DL-a-Lipoic acid 1,2-Dithiolane-3-pentanoic acid DL-PROTOGEN A (±)-1,2-Dithiolane-3-pentanoic acid DL-ALPHA-LIPOIC ACID UNII:73Y7P0K73Y DL-6,8-Thioctic acid TIMTEC-BB SBB003484 (S)-5-(1,2-Dithiolan-3-yl)pentanoic acid dl-6-Thiocticacid 5-(dithiolan-3-yl)valeric acid 5-(1,2)Dithiolan-3-yl-pentanoic acid (1)-ALPHA-LIPOIC ACID A-LIPOIC ACID (+/-)-1,2-DITHIOLANE-3-VALERIC ACID DL-ThioCLic Acid DL-α-Lipoic acid DL-6,8-THIOOCTIC ACID 5-(dithiolan-3-yl)pentanoic acid 6,8-Dithiooctanoic acid THIOOCTIC ACID 1,2-DITHIOLANE-3-VALERIC ACID DL-6,8-THIOCTIC ACID OXIDIZED FORM (+-)-2-dithiolane-3-valericacid (+/-)-alpha-Lipoic acid >= lipoic acid DL-6,8-Thioctic acid Lip(S2) EINECS 214-071-2 alpha-lipoic acid (CAS ) Alpha-Thioctic Alpha-lipoic acid,free flowing agent 5-[(3S)-Dithiolan-3-yl]pentanoic acid (+/-)-ALPHA-LIPOIC ACID Thioctic acid, dl-form DL-THIOCTIC ACID DL-6,8-DITHIOOCTANOIC ACID DL-α-Lipoic acid, (Assay) D-[3-(1,2-DITHIACYCLOPENTYL)]PENTANOIC ACID DITHIOOCTANIC ACID 1,2-Dithiolane-3-pentanoicacid,(+-)-(9CI) LIPOIC ACID, DL-ALPHA-(AS) DL-6,8-THIOCTIC ACID DL-1,2-DITHIOLANE-3-PENTANOIC ACID dl-1,2-Dithiolane3-valericacid Dl-ThiocticAcid,Oxidized (+/-)-2-dithiolane-3-pentanoicacid Thioctic acid THIOCTIC ACID DL-Thioctic acid, R (±)-α-Lipoic acid DL-6-Thioctic acid (-ALPHA-LIPOIC ACID (-ALPHA-LIPOIC ACID LIP(S2) (RS)-a-Lipoic Acid (±)-1,2-Dithiolane-3-valeric acid 6,8-DITHIOOCTANOIC ACID ALPHA-LIPONIC ACID rac a-Lipoic Acid 6,8-Dihydrothioctic acid α-Lipoic Acid ((±)-α-Lipoic acid |
| Description | α-Lipoic Acid is an antioxidant, which is an essential cofactor of mitochondrial enzyme complexes. α-Lipoic Acid inhibits NF-κB-dependent HIV-1 LTR activation. |
|---|---|
| Related Catalog | |
| Target |
NF-κB HIV Mitochondrial bioenergetics |
| In Vitro | The long terminal repeat (LTR) of HIV-1 is the target of cellular transcription factors such as NF-κB, and serves as the promoter-enhancer for the viral genome when integrated in host DNA[1]. α-Lipoic Acid (Alpha-Lipoic acid, ALA), a naturally occurring dithiol compound, plays an essential role in mitochondrial bioenergetics. α-Lipoic Acid reduces lipid accumulation in the liver by regulating the transcriptional factors SREBP-1, FoxO1, and Nrf2, and their downstream lipogenic targets via the activation of the SIRT1/LKB1/AMPK pathway. Treatment of cells with α-Lipoic Acid (250, 500 and 1000 μM) significantly increases the NAD+/NADH ratio in HepG2 cells (P<0.05 or P<0.01). Treatment with α-Lipoic Acid (50, 125, 250 and 500 μM) increases SIRT1 activity in HepG2 cells. α-Lipoic Acid (50, 125, 250, 500 and 1000 μM) increases phosphorylation of AMPK and acetyl-CoA carboxylase (ACC) in HepG2 cells in a dose-dependent fashion[1]. |
| In Vivo | C57BL/6J mice, divided into four groups, are fed an high-fat diet (HFD) for 24 weeks to induce nonalcoholic fatty liver disease (NAFLD) followed by daily administration of α-Lipoic Acid. Then, the effects of α-Lipoic Acid on hepatic lipid accumulation in long-term HFD-fed mice are assessed. Administration of α-Lipoic Acid (100 mg/kg or 200 mg/kg) markedly reduces visceral fat mass in mice. In addition, α-Lipoic Acid (100 mg/kg or 200 mg/kg) treatment inhibits the appetite and causes a dramatic weight loss (all P<0.05)[1]. |
| Cell Assay | The human hepatocellular carcinoma (HepG2) cell line is cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum at 37°C and 5% CO2. HepG2 cells are treated with AMPK inhibitor (CC, 20 μM, 0.5 h), SIRT1 inhibitor (NA, 10 mM, 12 or 24 h), and AMPK activator (AICAR, 2 mM, 1 h), Palmitate (PA, 125 μM, 12 h) and α-Lipoic Acid (250 μM, 6 or 12 h)[1]. |
| Animal Admin | Mice[1] Male C57BL/6J mice (6-week-old; body weight: 22-24 g) are allowed ad libitum access to normal diet and water for 2 weeks before dividing into four groups (n=8): normal diet (ND) (10% energy from fat), high-fat diet (HFD) (60% energy from fat) and HFD plus α-Lipoic Acid (100 mg/kg or 200 mg/kg). After 24 weeks of treatment, blood samples are collected after the eyeballs of the mice are extracted for serum preparation by centrifugation at 2000×g for 10 min at 4°C. The liver tissues are harvested in liquid nitrogen and stored at -80°C. |
| References |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 362.5±11.0 °C at 760 mmHg |
| Melting Point | 60-62ºC |
| Molecular Formula | C8H14O2S2 |
| Molecular Weight | 206.326 |
| Flash Point | 173.0±19.3 °C |
| Exact Mass | 206.043518 |
| PSA | 87.90000 |
| LogP | 2.16 |
| Vapour Pressure | 0.0±1.7 mmHg at 25°C |
| Index of Refraction | 1.562 |
| Storage condition | 2-8°C |
| Stability | Stable. Incompatible with strong oxidizing agents. |
| Water Solubility | ethanol: 50 mg/mL | 0.9 g/L (20 ºC) |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302 |
| Precautionary Statements | P301 + P312 + P330 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xn: Harmful; |
| Risk Phrases | R22 |
| Safety Phrases | 37/39-26-24/25-36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
| RTECS | JP1192000 |
| HS Code | 2934999090 |
| Precursor 7 | |
|---|---|
| DownStream 9 | |
| HS Code | 2934999090 |
|---|---|
| Summary | 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |